191 related articles for article (PubMed ID: 18754028)
21. TNF-α expression in tumor cells as a novel prognostic marker for diffuse large B-cell lymphoma, not otherwise specified.
Nakayama S; Yokote T; Hirata Y; Akioka T; Miyoshi T; Hiraoka N; Iwaki K; Takayama A; Nishiwaki U; Masuda Y; Nishimura Y; Tsuji M; Hanafusa T
Am J Surg Pathol; 2014 Feb; 38(2):228-34. PubMed ID: 24145654
[TBL] [Abstract][Full Text] [Related]
22. BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma.
Obermann EC; Csato M; Dirnhofer S; Tzankov A
J Clin Pathol; 2009 Oct; 62(10):903-7. PubMed ID: 19783718
[TBL] [Abstract][Full Text] [Related]
23. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
Nyman H; Jerkeman M; Karjalainen-Lindsberg ML; Banham AH; Enblad G; Leppä S
Eur J Haematol; 2009 May; 82(5):364-72. PubMed ID: 19141121
[TBL] [Abstract][Full Text] [Related]
24. Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma.
Xia B; Zhang L; Guo SQ; Li XW; Qu FL; Zhao HF; Zhang LY; Sun BC; You J; Zhang YZ
World J Gastroenterol; 2015 Feb; 21(8):2433-42. PubMed ID: 25741152
[TBL] [Abstract][Full Text] [Related]
25. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
[TBL] [Abstract][Full Text] [Related]
26. High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma.
Green TM; Nielsen O; de Stricker K; Xu-Monette ZY; Young KH; Møller MB
Am J Surg Pathol; 2012 Apr; 36(4):612-9. PubMed ID: 22314191
[TBL] [Abstract][Full Text] [Related]
27. Cytogenetic features of de novo CD5-positive diffuse large B-cell lymphoma: chromosome aberrations affecting 8p21 and 11q13 constitute major subgroups with different overall survival.
Yoshioka T; Miura I; Kume M; Takahashi N; Okamoto M; Ichinohasama R; Yoshino T; Yamaguchi M; Hirokawa M; Sawada K; Nakamura S
Genes Chromosomes Cancer; 2005 Feb; 42(2):149-57. PubMed ID: 15543600
[TBL] [Abstract][Full Text] [Related]
28. [Clinical characteristics and prognosis of concurrent positive t(14; 18) and myc gene rearrangement in diffuse large B cell lymphoma].
Zhang HW; Chen ZW; Wang LY; He JX; Zheng YP; Han WE; Yang B; Wang YL; Zhao ZQ; Bai M; Su LP
Zhonghua Zhong Liu Za Zhi; 2016 Mar; 38(3):206-10. PubMed ID: 26988827
[TBL] [Abstract][Full Text] [Related]
29. MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC/BCL2 protein double-positive diffuse large B-cell lymphoma.
Wang XJ; Medeiros LJ; Lin P; Yin CC; Hu S; Thompson MA; Li S
Am J Surg Pathol; 2015 Sep; 39(9):1250-8. PubMed ID: 25828389
[TBL] [Abstract][Full Text] [Related]
30. p53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: a single institutional clinicopathologic study.
Xie Y; Bulbul MA; Ji L; Inouye CM; Groshen SG; Tulpule A; O'Malley DP; Wang E; Siddiqi IN
Am J Clin Pathol; 2014 Apr; 141(4):593-604. PubMed ID: 24619762
[TBL] [Abstract][Full Text] [Related]
31. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
32. Double-hit BCL2/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma - a single centre's experience.
Pedersen MØ; Gang AO; Poulsen TS; Knudsen H; Lauritzen AF; Nielsen SL; Gang UO; Nørgaard P
Eur J Haematol; 2012 Jul; 89(1):63-71. PubMed ID: 22510149
[TBL] [Abstract][Full Text] [Related]
33. C-MYC overexpression predicts aggressive transformation and a poor outcome in mucosa-associated lymphoid tissue lymphomas.
Huang W; Guo L; Liu H; Zheng B; Ying J; Lv N
Int J Clin Exp Pathol; 2014; 7(9):5634-44. PubMed ID: 25337204
[TBL] [Abstract][Full Text] [Related]
34. Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma.
Horn H; Ziepert M; Wartenberg M; Staiger AM; Barth TF; Bernd HW; Feller AC; Klapper W; Stuhlmann-Laeisz C; Hummel M; Stein H; Lenze D; Hartmann S; Hansmann ML; Möller P; Cogliatti S; Pfreundschuh M; Trümper L; Loeffler M; Glass B; Schmitz N; Ott G; Rosenwald A;
Leukemia; 2015 Jul; 29(7):1564-70. PubMed ID: 25687653
[TBL] [Abstract][Full Text] [Related]
35. CD30 expression and its correlation with MYC rearrangement in de novo diffuse large B-cell lymphoma.
Wang XJ; Seegmiller AC; Reddy NM; Li S
Eur J Haematol; 2016 Jul; 97(1):39-47. PubMed ID: 26340843
[TBL] [Abstract][Full Text] [Related]
36. Primary breast non-Hodgkin's lymphoma: a large single center study of initial characteristics, natural history, and prognostic factors.
Validire P; Capovilla M; Asselain B; Kirova Y; Goudefroye R; Plancher C; Fourquet A; Zanni M; Gaulard P; Vincent-Salomon A; Decaudin D
Am J Hematol; 2009 Mar; 84(3):133-9. PubMed ID: 19199367
[TBL] [Abstract][Full Text] [Related]
37. Clinical and Pathologic Correlation of Increased MYC Gene Copy Number in Diffuse Large B-Cell Lymphoma.
Haws BT; Cui W; Persons DL; Zhang D
Clin Lymphoma Myeloma Leuk; 2016 Dec; 16(12):679-683. PubMed ID: 27633159
[TBL] [Abstract][Full Text] [Related]
38. Assessing DcR3 expression in relation to survivin and other prognostic factors in B cell non-Hodgkin's lymphoma.
Bedewy AM; Elgammal MM; Bedewy MM; El-Maghraby SM
Ann Hematol; 2013 Oct; 92(10):1359-67. PubMed ID: 23652586
[TBL] [Abstract][Full Text] [Related]
39. Topo IIα gene alterations correlated with survival in patients with diffuse large B-cell lymphoma.
Chen Z; Wang J; Zhang H; Liu D; Li Y; Xu Y; Tan D; Chen D; Zhao X; Wang G
Eur J Clin Invest; 2012 Mar; 42(3):310-20. PubMed ID: 21880040
[TBL] [Abstract][Full Text] [Related]
40. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
Oki Y; Yamamoto K; Kato H; Kuwatsuka Y; Taji H; Kagami Y; Morishima Y
Eur J Haematol; 2008 Dec; 81(6):448-53. PubMed ID: 18691256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]